


Identification of metabolites: analytical challenges for conducting *in vitro* metabolism characterisation of pesticides




Outline

Introduction

Analytical aspects

Data processing

Conclusions



Why do we need to identify metabolites?


Metabolites can affect the efficacy and safety of potential drugs

- Efficacy
 - The metabolites modulate the efficacy of drugs in the treatment of disease
 - Metabolites may possess pharmacological activity
- Safety
 - Metabolite may be toxic (bioactivation)
 - Active metabolites and reactive metabolites may impact on safety



Pharmaceutical Companies are mandated
by Regulatory Agencies to identify metabolites of NCEs


What is the stage-based need for metabolite identification?



- In discovery stage:
 - Address clearance issues (metabolic hot-spots) leading to short half-life
 - Provide biotransformation pathway information for candidate selection as well as during lead optimisation
 - Generate potential new leads
 - Eliminate compounds that produce potentially reactive metabolites
- In development stage:
 - Determine metabolic pathways in preclinical species and in humans
 - Attempt to model metabolism in humans
 - Ensure that the preclinical species chosen for safety evaluation are adequate
 - Ensure all major metabolites are monitored

Metabolite identification workflow

Continuous and iterative process



Identification confidence






| Example | Identification confidence | Minimum data requirements |
|---|---|--|
|  | Level 1: Confirmed structure by reference standard | MS, MS ² , RT, Reference Std. |
| | Level 2: Probable structure a) by library spectrum match b) by diagnostic evidence | MS, MS ² , Library MS ² MS, MS ² , Exp. data |
|  | Level 3: Tentative candidate(s) structure, substituent, class | MS, MS ² , Exp. data |
|  | Level 4: Unequivocal molecular formula | MS isotope/adduct |
|  | Level 5: Exact mass of interest | MS |

Figure 1. Proposed identification confidence levels in high resolution mass spectrometric analysis. Note: MS² is intended to also represent any form of MS fragmentation (e.g., MS^e, MSⁿ).

LC separation

Samples should be analysed using generic LC conditions to balance adequate retention and reasonable elution times of various metabolites

Co-elution of metabolites should be avoided case of isobaric species and as well as liquid chromatography coupled to UV/radio detection




Metabolite characterisation: Mass spectrometry

Tandem Mass Spectrometry

technique to identify metabolites in complex biological matrices

Equipment

- Triple Quadrupole (QQQ)
- Ion Traps (IT and LIT)
- Q-Orbitrap
- Q-Time Of Fly (TOF)




| | | A, QQQ-MS | B, IT-MS | C, Q-TOF-MS | D, Orbi-MS |
|------------------|----------------------|-----------|----------|-------------|-----------------|
| Mass Resolution | | low | low | high | high/ultra-high |
| Sensitivity | Global acquisition | 1 | 2 | 3 | 3 |
| | Targeted acquisition | 3 (4) | 2 (3) | (2) 3 | (2) 3 |
| Specificity | Global acquisition | 1 | 1 | (2) 3 | 3 (4) |
| | Targeted acquisition | 3 | (3) 4 | (3) 4 | 4 (5) |
| Acquisition rate | Global acquisition | 1 | 3 | (3) 4 | 3 |
| | Targeted acquisition | 3 | 2 | (2) 3 | 2 |
| Sum | Global acquisition | 3 | 6 | 8-10 | 9-10 |
| | Targeted acquisition | 9-10 | 7-9 | 7-10 | 8-10 |

Fig. 2. Scheme of the 4 most used LC-MS technologies: 2 low resolution technologies, triple quadrupole (A: QQQ-MS) and ion trap MS (B: IT-MS) and 2 high resolution technologies, quadrupole-time-of-flight-MS (C: Q-TOF) and quadrupole-orbitrap-MS (D: Q-Orbi); adapted from [12]. The table below allocates a grade according to global or targeted MS performance (1 to 5 points for poor to excellent, respectively). Global acquisition corresponds to high resolution full scan (HR-MS) or data-independent-acquisition (DIA). Targeted acquisition corresponds to SIM (single ion monitoring), SRM (selected reaction monitoring) or product ion scan. Sensitivity, specificity and acquisition rate (scan speed) are considered and points are summed in the last row. **Abbreviations.** CC: collision cell; d: detector; F: flight; FT: Fourier transform; IT: ion trap; O: orbitrap; p: pusher; Q: quadrupole; r: reflectron; Δt : delta of time.

Accurate mass measurement

Metabolite Characterization using Mass Spectrometry




Take advantage of Nature's imperfection!

Resolution and accuracy

Metabolite characterisation using Mass Spectrometry

Resolution

in mass spectrometry, is a measure of the ability to distinguish between two peaks of different mass-to-charge ratio (m/z) in a mass spectrum.





Accurate Mass Measurement

$$\text{ppm} = \frac{m/z_{\text{Observed}} - m/z_{\text{Theoretical}}}{m/z_{\text{Theoretical}}} (10)^6$$

Accurate mass measurement

Exact Mass can confirm and distinguish elemental composition for metabolites with the same nominal mass




M1
 Exact mass (theor.): 242.0793
 Formula= C₁₂H₁₁NOF₃
 ppm error= -4.1

M2
 Exact mass (theor.): 242.0429
 Formula= C₁₁H₇NO₂F₃
 ppm error= 146.2

Obtained using QToF II

Resolution and isotopic distribution

Metabolite characterisation using mass spectrometry



FWHM= 50000

FWHM= 5000

FWHM= 500

Even highest mass accuracy and resolution, however, is not sufficient to determine the unique chemical formula of each ion

Isotope pattern evaluation can be useful to reduce the search space and determine the molecular formula

HR mass spectrometer




| HRMS | Q-Orbitrap | QTOF | QTOF | Q-TOF and IT-TOF | Q-TOF |
|----------|----------------------|------------------|--------|------------------|---------------|
| Software | Compound Discoverer™ | MetabolitePilot™ | UNIFI™ | MetID solution | Mass MetaSite |

Data Elaboration is the bottleneck of Metabolite Identification


Metabolite characterisation: Mass spectrometry

Acquisition process


Data Dependent Analyses



Data Independent Analyses



Polarity switching in metabolite profiling




It can be advantageous to screen for metabolites using both positive and negative ionization modes.

This is especially true for phase II metabolism which tends to make molecules more polar and often more acidic

POSITIVE ion mode

NEGATIVE ion mode



Functionality provided by Met ID profiling tools

- Identification of drug and related metabolites as chromatographic peaks from the complex TIC trace
- Assignment of chemical structures for each identified metabolite

Comparison with
Control

Biotransformation
List

Isotope filtering

Mass Defect
Filtering

MSMS acquisition
method creation

Formula
Prediction

MS/MS
Data
Interpretation

Linkage to
specific Database

Statistical
Analyses

Biotransformation list

Table 1 Effects of common phase I metabolic reactions on the mass-spectrometric behavior and retention in comparison with the parent drug

| Nominal mass shift (Δ Du) | Metabolic reaction (elemental composition change) | Exact mass shift (mDa) | Examples of relative retention shift ^a | References |
|-----------------------------------|--|------------------------|---|---|
| – | Azo reduction to amines ($R_1N = NR_2$ to $R_1NH_2 + R_2NH_2$) | – | – | [145] |
| –14x ^b | Hydrolysis of esters to carboxylic acid ($-C_2H_4O$) | –15.7x | – | [106] |
| –90 | Reductive debenzoylation ($-C_7H_6O$) | –47.0 | 0.74 [134] | [134] |
| –78 | Reductive debromination ($-Br+H$) | +89.5 | – | [113] |
| –74 | Oxidative debenzoylation ($-C_7H_6+O$) | –52.0 | – | [180] |
| –68 | Loss of CF_3 ($-CF_3+H$) | +12.6 | – | [107] |
| –62 | Oxidative debromination ($-Br+OH$) | +84.4 | 0.39 [17] | [17] |
| –56 | Debutylation ($-C_4H_8$) | –62.6 | – | [107] |
| –45 | Hydrolysis of nitrate to alcohol ($-NO_2+H$) | +14.9 | – | [113] |
| | Reductive loss of nitro group ($-NO_2+H$) | +14.9 | 1.37 [46] | [46, 106] |
| –44 | Decarboxylation ($-CO_2$) | +10.2 | – | [106] |
| –42 | Depropylation ($-C_3H_6$) | –47.0 | 0.73—isopropyl [131]; 0.85, 1.09—propyl [24] | [24, 131] |
| –36 | Loss of HCl ($-HCl$) | +23.3 | – | [148] |
| –34 | Reductive dechlorination ($-Cl+H$) | +39.0 | – | [148] |
| –30 | Nitro reduction to amine ($-O_2+H_2$) | +25.8 | 0.75 [144] | [144] |
| –28 | Deethylation ($-C_2H_5$) | –31.3 | 0.87 [76] | [76] |
| –25 | Reductive loss of nitrile group ($-CN+H$) | +4.8 | 0.88 [45] | [45, 106] |
| –18 | Alcohol dehydration ($-H_2O$) | +10.6 | 2.08 ^c [17] | [17] |
| | Oxidative dechlorination ($-Cl+OH$) | +33.9 | 0.73 [146] | [146] |
| | Reductive defluorination ($-F+H$) | +9.4 | – | [147] |
| –16 | Desulfuration ($-S+O$) | +22.8 | 0.54 [68] | [68] |
| | Reduction of sulfoxide to thioether ($-O$) | +5.1 | – | [113] |
| | Reduction of hydroxylamine to amine ($-O$) | +5.1 | – | [113] |
| –14 | O-demethylation ($-CH_3$) | –15.7 | 0.88, 0.93 [19]; 0.56, 0.64 [40]; 0.59 [129]; 0.87, 0.88, 0.90 [130] | [19, 25, 40, 46, 108, 129–131] |
| | N-demethylation ($-CH_3$) | –15.7 | 0.82 [52]; 0.84 [135]; 0.87 [51]; 0.88 [19]; 0.90 [40]; 0.92 [133]; 0.95 [130]; 0.99 [45] | [19, 40, 45, 47, 50–52, 130, 133, 135, 136] |
| | S-demethylation ($-CH_3$) | –15.7 | – | [132] |
| –6 | Aromatization of saturated ring ($-H_4$) | –47.0 | – | [152] |
| –2 | Alcohol oxidation to ketone/aldehyde ($-H_2$) | –15.7 | 1.01 [83] | [83, 106] |
| | Ring formation ($-H_2$) | –15.7 | 1.20 [112] | [112] |
| | Oxidative defluorination ($-F+OH$) | +4.3 | – | [77, 147] |
| –1 | Oxidative deamination to ketone/aldehyde ($-NH_3+O$) | –31.6 | – | [142] |
| +1 | Oxidative deamination to alcohol ($-NH+O$) | –16.0 | – | [113] |
| | Hydrolysis of amide to carboxyl ($-NH+O$) | –16.0 | – | [143] |
| +2 | Ketone/aldehyde reduction to alcohol ($+H_2$) | +15.7 | 0.72 [56]; 0.70 [40] | [33, 40, 56, 126] |
| | Hydrogenation ($+H_2$) | +15.7 | 1.13 [124] | [17, 124] |
| | Ring opening ($+H_2$) | +15.7 | 0.59 [149] | [47, 149–151] |


Table 1 (continued)

| Nominal mass shift (Δ Du) | Metabolic reaction (elemental composition change) | Exact mass shift (mDa) | Examples of relative retention shift ^a | References |
|-----------------------------------|--|------------------------|---|---|
| +14 | Methylmethylene oxidation to aldehyde/ketone ($+O-H_2$) | –20.7 | 0.92, 1.02 [102]; 1.05 [45] | [45, 102] |
| | Alcohol oxidation to carboxylic acid ($+O-H_2$) | –20.7 | – | [106] |
| | Hydroxylation and cyclization ($+O-H_2$) | –20.7 | – | [106] |
| +16 | Hydroxylation ($+O$) | –5.1 | 0.38 [51]; 0.40 [131]; 0.46 [137]; 0.46, 0.50, 0.62 [124]; 0.51, 0.73, 0.82, 0.89, 0.96 [76]; 0.56 [40]; 0.58 [135]; 0.60, 0.62 [112]; 0.61 [45]; 0.69 [130]; 0.80 [52]; 0.82 [138]; 0.85 [102] | [23, 24, 40, 45, 47, 51, 52, 76, 83, 102, 108, 112, 124, 130, 131, 135–139] |
| | Epoxidation ($+O$) | –5.1 | 0.56 [124]; 0.72 [140]; 0.89 [77] | [77, 124, 140, 141] |
| | N-oxidation ($+O$) | –5.1 | 0.93 [40]; 1.04 [45]; 1.09 [76] | [40, 45, 51, 76, 131, 136] |
| | S-oxidation of thioether to sulfoxide or sulfone to sulfone ($+O$) | –5.1 | 0.34 (S-SO) [141]; 0.82 (S-SO) [138]; 1.02 (SO-SO ₂) [143] | [138, 141, 143] |
| | Aldehyde oxidation to carboxyl ($+O$) | –5.1 | – | [126] |
| | Oxidation and ring formation ($+O$) | –5.1 | 0.46, 0.51 [137]; 0.53, 0.64 [80] | [80, 137] |
| +18 | Ring opening by water addition ($+H_2O$) | +10.6 | 1.10 [18] | [18, 19] |
| | Hydrolysis of nitrile to amide ($+H_2O$) | +10.6 | – | [45] |
| +30 | Methyl oxidation to carboxylic acid ($+O_2-H_2$) | –25.8 | 0.24 [167]; 0.34 [40] | [40, 50, 167] |
| +32 | Dihydroxylation ($+O_2$) | –10.2 | 0.49 [54]; 0.39 [124]; 0.80, 0.81 [160]; 0.84 [83]; 0.63, 0.67, 0.71, 0.79, 0.94 [76] | [54, 76, 83, 124, 160] |
| | S-oxidation of thioether to sulfone ($+O_2$) | –10.2 | 0.79 [138] | [138] |
| +34 | Epoxidation and hydmtion ($+H_2O_2$) | +5.5 | 0.39 [124]; 0.47 [140]; 0.51, 0.68 [141] | [124, 140, 141] |
| +48 | Trihydroxylation ($+O_3$) | –15.3 | – | [113] |
| | S-oxidation of thiol to sulfonic acid ($+O_3$) | –15.3 | – | [113] |

^a The parent drug has a relative retention shift (RRS) of 1.00.

^b The value of x corresponds to the length of the alkyl chain.

^c RRS is related to another metabolite.



Biotransformation list

- M1
Cleavage to Epicatechin
- M2-M6
Conjugation of Epicatechin
- M7-M9
C-Ring Cleavage of Epicatechin
- M10-M11
Phenylvalerolactone Metabolites
- M12-M13
Phenylvalenic Acid Metabolites
- M14-M20
Phenylpropionic Acid Metabolites
- M21-M23
Phenylacetic Acids Metabolites
- M24-M27
Benzoic Acid Metabolites









FIGURE 5 | The proposed metabolic pathway of 45 identified metabolites of procyanidin B2 in mice.

Isotopic filtering

Discriminate metabolites based on characteristic isotopic pathway



Conjugated metabolites



- Used as post-acquisition data processing tool
- Less recommended triggering DDA experiments

Mass defect filter

Proposed metabolites of Atrazine (ATZ)

DEALKYLATED METABOLITES

DACT, diaminochlorotriazine

DEA, desethylatrazine

DIA, desisopropyl atrazine

HYDROXYLATED METABOLITES

ATZ-OH, hydroxyatrazine

DEA-OH, hydroxydesethylatrazine

Ammeline

GLUTATHIONE-DERIVED MERCAPTURIC ACID


AM, atrazine mercapturate

DEAM, desethylatrazine mercapturate

DIAM, desisopropylatrazine mercapturate

DATM, diaminotriazine mercapturate

| ID | Description of the Biotransformation | Nominal Mass shift (Da) |
|----------|--|-------------------------|
| AM | Dechlorination Mercapturic acid conj. | 127 |
| DEAM | Dechlorination Mercapturic acid conj. N-dealkylation | 99 |
| DIAM | Dechlorination Mercapturic acid conj. N-dealkylation | 85 |
| DATM | Dechlorination Mercapturic acid conj. N-dealkylation | 57 |
| DEA | N-dealkylation | -28 |
| DIA | N-dealkylation | -42 |
| DACT | N-dealkylation | -70 |
| ATZ-OH | Oxidative dechlorination | -18 |
| DEA-OH | N-dealkylation & Oxidative dechlorination | -46 |
| Ammeline | N-dealkylation & Oxidative dechlorination | -88 |



Mass defect filter

Mass Defect Filter (MDF)

Difference between the exact mass of an element (or a compound) and its closest integer value


- Used as post-acquisition data processing tool
- Some software consider MDF filtering accordingly to predicted cleavage products

| ID | Description of the Biotransformation | Formula Change | Nominal Mass shift (Da) | Accurate Mass Shift (Da) | Mass Defect (mDa) |
|-----------|--|----------------|-------------------------|--------------------------|-------------------|
| AM | Dechlorination Mercapturic acid conj. | -Cl, +C5H8NO3S | 127 | 127.0536 | 53.6 |
| DEAM | Dechlorination Mercapturic acid conj. N-dealkylation | -Cl, +C3H4NO3S | 99 | 99.0223 | 22.3 |
| DIAM | Dechlorination Mercapturic acid conj. N-dealkylation | -Cl, +C2H2NO3S | 85 | 85.0067 | 6.7 |
| DATM | Dechlorination Mercapturic acid conj. N-dealkylation | -ClH2, +NO3S | 57 | 56.9754 | -24.6 |
| ATZ-OH | Oxidative dechlorination | -Cl, +HO | -18 | -17.9661 | 33.9 |
| DEA | N-dealkylation | -C2H4 | -28 | -28.0313 | -31.3 |
| DIA | N-dealkylation | -C3H6 | -42 | -42.0470 | -47.0 |
| DEA-OH | N-dealkylation & Oxidative dechlorination | -ClC2H3, +O | -46 | -45.9974 | 2.6 |
| DACT | N-dealkylation | -C5H10 | -70 | -70.0783 | -78.3 |
| Ammieline | N-dealkylation & Oxidative dechlorination | -ClC5H9, +O | -88 | -88.0444 | -44.4 |

MS/MS data interpretation

While assigning the structures, some software predict the theoretical fragments for the parent drug and metabolites, and assign/compares them with experimentally obtained MS/MS results



In absence of standard structural assignments are always tentative





Cross species comparison

- Identify human metabolites that differ from those observed in animal models, assisting pre-clinical safety and toxicity studies
- inter-species metabolic stability assessment should be considered in study design

Reconstructed Ion Chromatogram (+ve and -ve) of Everolimus and its metabolites Observed in Dog live Microsome Following 30 min Incubation of Test Item at 1 μ M




Reconstructed Ion Chromatogram (+ve and -ve) of Everolimus and its metabolites Observed in Rat live Microsome Following 30 min Incubation of Test Item at 1 μ M



Cross species comparison

Peak Area is not necessarily proportional to analyte abundance, but it's associated to ionization efficiency of each analyte

In some cases the addition of complementary UV detection is sufficient for metabolite quantification




Conclusions

Take-home messages

- Study outcomes should meet stage-based needs
- LC-HRMS is the technique of choice
- Data processing is still the most demanding step
- Use customised processing workflow
- In absence of standards or complementary detection techniques mass spectrometry is not quantitative


QUESTIONS
AND ANSWERS



Your contact:

Business Development
114 Innovation Drive, Milton Park, Abingdon
Oxfordshire OX14 4RZ, UK

T: +44.(0)1235.86 15 61
F: +44.(0)1235.86 31 39
info@evotec.com



Your contact:

Maria Anna Fedrigo
Research Expert, Discovery DMPK

+39 045 8218325
+39 045 8218153 Fax
Maria.Fedrigo@Aptuit.com

